Skip to main content

Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases

CaSR Biomedicine

Start Date
End Date
Total Funding
€ 3 657 195
Funding Programme

The calcium sensing receptor (CaSR) is a class C Gprotein-coupled receptor that plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary Ca excretion. Abnormal CaSR function is implicated in calciotropic disorders, and in non-calciotropic disorders such as Alzheimer’s disease (AD), cardiovascular disease (CVD), diabetes (DM), sarcopenia and cancer, which account for >25% of the global disease burden. The CaSR is a unique GPCR whose principal physiological ligand is the Ca2\ ion; it is expressed almost ubiquitously; interacts with multiple Gα subtypes regulating highly divergent downstream signalling pathways, depending on the cellular context. The CaSR Biomedicine is a fully translational project that utilises the concept of a single molecule, the CaSR, influencing a range of physiological and disease processes, to develop a unique, strong multidisciplinary and intersectoral scientific training programme preparing 14 young scientists to become specialists in GPCR biology and signalling.
The objectives of CaSR Biomedicine are: 1. Educate and train Early Stage Researchers to become highly innovative scientists to enhance their career perspective. 2. Elucidate ligand- and tissue-dependent differences in CaSR physiology by examining its functions at cellular level and thus to contribute to the understanding of GPCR signalling in general; 3. Assess how CaSR function is altered in AD, CVD, DM, sarcopenia, and cancer, and to find innovative CaSR-based therapeutic approaches for these major, age-related disorders. 4. Establish long-lasting interdisciplinary and intersectoral cooperation among researchers and between researchers and industry, to strengthen the European Research Area. Therefore the CaSR Biomedicine will investigate the complexity of CaSR signalling and function to identify CaSR-based therapeutic approaches to diseases linked to changes in CaSR expression or function (AD, CVD, DM, sarcopenia, and cancer).

Project partners

S.A.F.An. Bioinformatics - Sas Di Pugliese Luisa
Universite De Picardie Jules Verne
Fundacio Sant Joan De Deu
The University Of Manchester
Stichting Vu
Universita Degli Studi Di Firenze
Kobenhavns Universitet
Biotalentum Tudasfejleszto Kft
Tissuegnostics Gmbh
The University Of Liverpool
The Chancellor
Masters And Scholars Of The University Of Oxford
Cardiff University
Fh Joanneum Gesellschaft Mbh
Novartis Pharma Ag
Amgen Gmbh
Imabiotech Sas
Medizinische Universitaet Wien

Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).